PTC Therapeutics Inc. (PTCT)
NASDAQ: PTCT
· Real-Time Price · USD
40.79
-9.16 (-18.34%)
At close: May 05, 2025, 3:59 PM
40.66
-0.32%
After-hours: May 05, 2025, 07:57 PM EDT
-18.34% (1D)
| Bid | 40 |
| Market Cap | 3.22B |
| Revenue (ttm) | 806.78M |
| Net Income (ttm) | -363.3M |
| EPS (ttm) | -4.73 |
| PE Ratio (ttm) | -8.62 |
| Forward PE | -25.92 |
| Analyst | Buy |
| Ask | 47.64 |
| Volume | 3,937,441 |
| Avg. Volume (20D) | 1,110,991.4 |
| Open | 38.91 |
| Previous Close | 49.95 |
| Day's Range | 38.76 - 49.88 |
| 52-Week Range | 28.72 - 58.38 |
| Beta | 0.58 |
About PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offer...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 20, 2013
Employees 939
Stock Exchange NASDAQ
Ticker Symbol PTCT
Website https://www.ptcbio.com
Analyst Forecast
According to 13 analyst ratings, the average rating for PTCT stock is "Buy." The 12-month stock price forecast is $60.5, which is an increase of 48.32% from the latest price.
Stock ForecastsNext Earnings Release
PTC Therapeutics Inc. is scheduled to release its earnings on May 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 day ago
-18.62%
PTC Therapeutics shares are trading lower. The com...
Unlock content with
Pro Subscription
1 month ago
-6.05%
PTC Therapeutics shares are trading lower after JP Morgan cut its price target on the stock from $78 to $75.
